Affordable Access

deepdyve-link
Publisher Website

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis.

Authors
  • Jara, Michele
  • Sidovar, Matthew F
  • Henney, Herbert R 3rd
Type
Published Article
Journal
Therapeutics and clinical risk management
Publication Date
Jan 01, 2015
Volume
11
Pages
1–7
Identifiers
DOI: 10.2147/TCRM.S75837
PMID: 25565851
Source
Medline
Keywords
License
Unknown

Abstract

Seizure and renal impairment rates among D-ER-naïve patients were consistent with published literature, yet rates among those prescribed D-ER during the year preceding treatment initiation were slightly lower than rates among D-ER-naïve patients. Given that D-ER is contraindicated in patients with history of seizure or moderate or severe renal impairment, lower rates may indicate that risk-minimization strategies contributed to the lower prevalence.

Report this publication

Statistics

Seen <100 times